CR20130534A - Nuevos derivados de imidazol útiles para el tratamiento de artritis - Google Patents
Nuevos derivados de imidazol útiles para el tratamiento de artritisInfo
- Publication number
- CR20130534A CR20130534A CR20130534A CR20130534A CR20130534A CR 20130534 A CR20130534 A CR 20130534A CR 20130534 A CR20130534 A CR 20130534A CR 20130534 A CR20130534 A CR 20130534A CR 20130534 A CR20130534 A CR 20130534A
- Authority
- CR
- Costa Rica
- Prior art keywords
- arthritis
- treatment
- derivatives useful
- compounds
- imidazol derivatives
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 206010003246 arthritis Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula siguiente: donde A, X y R1-R6 son como se describen en la presente, una sal farmacéutica del mismo, y una composición farmacéutica que contiene este compuesto; métodos para tratar dolor asociado con osteoartritis usando uno de los compuestos o una sal del mismo farmacéuticamente aceptable, y procesos para preparar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490222P | 2011-05-26 | 2011-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20130534A true CR20130534A (es) | 2014-03-12 |
Family
ID=46148987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20130534A CR20130534A (es) | 2011-05-26 | 2013-10-18 | Nuevos derivados de imidazol útiles para el tratamiento de artritis |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8648200B2 (es) |
| EP (1) | EP2714679A1 (es) |
| JP (1) | JP2014518886A (es) |
| KR (1) | KR20130143138A (es) |
| CN (1) | CN103562200A (es) |
| AR (1) | AR086254A1 (es) |
| AU (1) | AU2012259234A1 (es) |
| BR (1) | BR112013029692A2 (es) |
| CA (1) | CA2836240A1 (es) |
| CO (1) | CO6811858A2 (es) |
| CR (1) | CR20130534A (es) |
| DO (1) | DOP2013000276A (es) |
| EA (1) | EA201391568A1 (es) |
| EC (1) | ECSP13013047A (es) |
| IL (1) | IL229318A0 (es) |
| MA (1) | MA35128B1 (es) |
| MX (1) | MX2013013859A (es) |
| PH (1) | PH12013502435A1 (es) |
| SG (1) | SG195020A1 (es) |
| TN (1) | TN2013000434A1 (es) |
| TW (1) | TW201311658A (es) |
| WO (1) | WO2012161965A1 (es) |
| ZA (1) | ZA201308609B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871947B2 (en) | 2013-02-04 | 2014-10-28 | KingChem LLC | Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester |
| CN103467379A (zh) * | 2013-08-23 | 2013-12-25 | 江苏恒安化工有限公司 | 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法 |
| CN103601675B (zh) * | 2013-10-08 | 2015-10-28 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| CN103483250B (zh) * | 2013-10-08 | 2015-07-22 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| US9139507B2 (en) | 2013-12-09 | 2015-09-22 | KingChem LLC. | Process for the preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylate and its analogs |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| WO2015143240A2 (en) | 2014-03-19 | 2015-09-24 | Curza Global, Llc | Compositions and methods comprising 2-(acylamino)imidazoles |
| ES2838625T3 (es) | 2014-04-14 | 2021-07-02 | Shanghai hengrui pharmaceutical co ltd | Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos |
| US20170057943A1 (en) | 2015-08-17 | 2017-03-02 | Japan Tobacco Inc. | Hydroxytriazine compounds and pharmaceutical use thereof |
| EP3601232B1 (en) | 2017-03-31 | 2022-11-23 | Curza Global LLC | Compositions and methods comprising substituted 2-aminoimidazoles |
| CN109293567A (zh) * | 2018-11-23 | 2019-02-01 | 上海睿腾医药科技有限公司 | 一种5-溴-2-甲基烟酸乙酯的合成方法 |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4458810A4 (en) | 2021-12-28 | 2025-12-17 | Nippon Shinyaku Co Ltd | INDAZOLE COMPOUND AND PHARMACEUTICAL PRODUCT |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN119161260A (zh) * | 2024-06-26 | 2024-12-20 | 安徽大学 | 一种1-（2-氨基-4-氟-5-甲氧基苯基）-1-丙酮的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1802605A1 (en) * | 2004-10-15 | 2007-07-04 | Amgen, Inc | Imidazole derivatives as vanilloid receptor ligands |
| US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| US20100324086A1 (en) | 2008-02-19 | 2010-12-23 | Novasaid Ab | Compounds and methods |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010127152A2 (en) | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| AR084174A1 (es) * | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
-
2012
- 2012-05-03 AR ARP120101556A patent/AR086254A1/es not_active Application Discontinuation
- 2012-05-04 TW TW101116086A patent/TW201311658A/zh unknown
- 2012-05-10 SG SG2013085154A patent/SG195020A1/en unknown
- 2012-05-10 AU AU2012259234A patent/AU2012259234A1/en not_active Abandoned
- 2012-05-10 CN CN201280025230.2A patent/CN103562200A/zh active Pending
- 2012-05-10 KR KR1020137030893A patent/KR20130143138A/ko not_active Ceased
- 2012-05-10 EP EP12723323.7A patent/EP2714679A1/en not_active Withdrawn
- 2012-05-10 MX MX2013013859A patent/MX2013013859A/es unknown
- 2012-05-10 EA EA201391568A patent/EA201391568A1/ru unknown
- 2012-05-10 PH PH1/2013/502435A patent/PH12013502435A1/en unknown
- 2012-05-10 CA CA2836240A patent/CA2836240A1/en not_active Abandoned
- 2012-05-10 US US13/468,122 patent/US8648200B2/en not_active Expired - Fee Related
- 2012-05-10 WO PCT/US2012/037200 patent/WO2012161965A1/en not_active Ceased
- 2012-05-10 JP JP2014512861A patent/JP2014518886A/ja active Pending
- 2012-05-10 BR BR112013029692A patent/BR112013029692A2/pt not_active IP Right Cessation
-
2013
- 2013-10-18 CR CR20130534A patent/CR20130534A/es unknown
- 2013-10-24 TN TNP2013000434A patent/TN2013000434A1/fr unknown
- 2013-11-07 IL IL229318A patent/IL229318A0/en unknown
- 2013-11-15 ZA ZA2013/08609A patent/ZA201308609B/en unknown
- 2013-11-15 MA MA36452A patent/MA35128B1/fr unknown
- 2013-11-22 CO CO13275568A patent/CO6811858A2/es not_active Application Discontinuation
- 2013-11-22 DO DO2013000276A patent/DOP2013000276A/es unknown
- 2013-11-25 EC ECSP13013047 patent/ECSP13013047A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2714679A1 (en) | 2014-04-09 |
| MA35128B1 (fr) | 2014-05-02 |
| TW201311658A (zh) | 2013-03-16 |
| JP2014518886A (ja) | 2014-08-07 |
| AU2012259234A1 (en) | 2013-11-14 |
| CA2836240A1 (en) | 2012-11-29 |
| MX2013013859A (es) | 2014-05-28 |
| BR112013029692A2 (pt) | 2017-01-17 |
| CO6811858A2 (es) | 2013-12-16 |
| KR20130143138A (ko) | 2013-12-30 |
| ECSP13013047A (es) | 2014-01-31 |
| CN103562200A (zh) | 2014-02-05 |
| US8648200B2 (en) | 2014-02-11 |
| DOP2013000276A (es) | 2014-03-31 |
| AR086254A1 (es) | 2013-11-27 |
| IL229318A0 (en) | 2014-01-30 |
| TN2013000434A1 (en) | 2015-03-30 |
| ZA201308609B (en) | 2015-05-27 |
| EA201391568A1 (ru) | 2014-04-30 |
| US20120302608A1 (en) | 2012-11-29 |
| WO2012161965A1 (en) | 2012-11-29 |
| SG195020A1 (en) | 2013-12-30 |
| PH12013502435A1 (en) | 2014-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130534A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CR20140301A (es) | Derivados de betulina | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2012008874A (es) | Macrociclos como inhibidores del factor de coagulacion (fxia). | |
| EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
| MX345763B (es) | Nuevos macrociclos como inhibidores del factor xia. | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| UY32200A (es) | Pirazolilaminopiridinas como inhibidores de fak | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| MX381235B (es) | Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. | |
| CR20120177A (es) | Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes | |
| ECSP14013239A (es) | Composiciones farmacéuticas | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| UY35143A (es) | Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| UY35325A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep |